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Abstract Psoriatic arthritis (PsA) is a chronic inflammatory
arthropathyassociatedwithpsoriasisthataffectstheperipheral
joints, spine, and entheses. Most patients with PsA present
with peripheral synovitis of the oligoarticular or polyarticular
subtype. As one of the targets of this disease, studies on the
synovium may provide insight into the mechanisms involved
in this condition. Key findings from the available studies
comparing synovial tissue of PsA and rheumatoid arthritis
patients are discussed in this review. Also, changes in the
synovial infiltrate, expression of proinflammatory cytokines
and adhesion molecules, and vascularity in synovial tissue
after treatment with various medications are addressed.
Finally, a model for proof-of-principle study design using
serial synovial biopsies is described, which could be used to
predictclinical(in)efficacyinearlyclinicaltrialdesigninPsA.
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Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy
of unknown etiology that is associated with psoriasis. It can
affect the peripheral joints, spine, and entheses. Belonging to
the spondyloarthritis (SpA) family, PsA is distinguished from
rheumatoid arthritis (RA), the most common inflammatory
arthropathy, by infrequent seropositivity for rheumatoid factor
and anti-citrullinated peptide antibodies, as well as the presence
of distinctive clinical features. These features include the
involvement of the distal interphalangeal (DIP) joints; an
asymmetric distribution of the inflamed joints; the presence of
dactylitis (inflammation of an entire digit [finger or toe]),
enthesitis, sacroiliitis, or spinal involvement; and, of course,
psoriasis. Radiological changes in PsA can present as erosive
lesions or osteolysis but also as periarticular new bone
formation. Joint destruction is often progressive, with almost
50% of PsA patients from an early arthritis clinic showing
radiological damage 2 years after first presentation [1], and the
the degree of radiological damage in PsA is comparable to
RA [2].
More than 35 years ago, Moll and Wright [3] described a
large case series of patients with PsA on which they based a
subdivision into five clinical phenotypes: polyarthritis, asym-
metrical oligoarthritis, spondylitis, predominant DIP arthritis,
and arthritis mutilans. This clinical heterogeneity and the
difficulty classifying patients with PsA correctly has been a
major concern over the years and may have hampered our
pathophysiologic understanding of the disease. Most patients
of the original cohort of Moll and Wright [3] were classified
in the oligoarticular subgroup (70%), and a minority in the
other subgroups. In later cohorts, polyarticular PsA was
usually the largest subgroup, at about 60% of the patients,
as was put forward by Helliwell and Taylor [4]. The reasons
for this discrepancy are not completely clear, but some have
argued that these later cohorts may have included patients
with seronegative RAwith coincident psoriasis [4]. Moreover,
the disease pattern in an individual patient can change over
time as a result of evolution of the disease or treatment [5].
Recently, data from a large cohort were prospectively
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Arthritis) study (588 PsA patients, 525 controls with other
inflammatory diseases, 70% of whom had RA) with the aim
of constructing new classification criteria from patient-derived
data [6]. Interestingly, when the collected data from this large
cohort were investigated, it turned out that the patients with
polyarticular PsA resembled those with oligoarticular PsA in
several ways, much more so than they resembled patients with
RA [7]. Thus, misclassification of seronegative RA as
polyarticular PsA does not seem to be a major problem.
It has been hypothesized by some authors that PsA is mainly
an entheseal disease [8]. Anatomically linking mechanical
stress (entheses) to immunologically active tissue (synovium),
the concept of the synovioenthesial complex (SEC) supports
this hypothesis [9, 10￿, 11￿]. Imaging studies have suggested
that tendon and ligament insertion points to bone (entheses)
are commonly subject to microdamage. Although the normal
enthesis is avascular in its fibrocartilaginous region, micro-
damage to the entheses is associated with local cytokine
release, tissue repair responses, and vessel ingrowth, which
may evolve into subsequent inflammation. It also has been
suggested that adjuvant molecules derived from bacteria may
be preferentially deposited at the site of the SEC; hence,
microdamage and propensity for bacterial molecule deposition
in the context of certain genetic factors may lead to the
characteristic inflammatory changes seen at the entheses in
SpA, including PsA [11￿]. Furthermore, because the nail is
functionally integrated with the SEC associated with the DIP
joints, this model provides a rationale for the combination of
DIP arthritis and nail involvement that is often observed in
PsA patients [9].
Whereas this model may provide a good explanation for
entheseal-relatedinflammationandarthritis(eg,asobservedin
the DIP joints), it does not where there is no close relationship
between the inflamed joints and enthesis or skin. As reported
above, most patients with PsA in the major cohorts seem to
have oligoarticular or polyarticular peripheral synovitis.
Because the synovium is a primary site of inflammation in
this disease, there has been increasing interest in studies of the
synovial tissue from patients with RA or PsA. In addition to
the use of synovial biopsies for diagnostic purposes [12, 13]
and pathogenetic studies [14, 15], serial synovial biopsies
could be used to evaluate the effects of treatments [16￿, 17].
This approach may have merit in screening for potential
efficacy during early drug development.
Immunohistochemistry of Synovial Tissue in Psoriatic
Arthritis Compared With Rheumatoid Arthritis
Several studies have characterized the synovium in PsA
compared with RA [15, 18–25], with variable results. In
general, it is good to realize that there are large differences
in synovial infiltrate and expression of proteins on an
individual patient level, so all findings reported are on the
group level. Confounding factors, such as differences in the
use of antirheumatic drugs between both groups and the
selection of patients, may have influenced the results of
some studies. Also, that synovial tissue was collected in
different ways (eg, arthroscopic or needle biopsies vs tissue
obtained during joint replacement surgery) may account for
some of the observed differences.
It has been suggested by several studies that the PsA
synovium is characterized by less pronounced lining layer
hyperplasia and fewer monocytes/macrophages than are seen
inRA [18, 23]. One group found fewer T and B cells in SpA
synovium [22], while others reported fewer T cells in PsA
synovial tissue in comparison with RA [15, 23, 25]. This is
remarkable because psoriasis and PsA are thought of as T-
cell–driven conditions. The lower number of T cells in PsA
synovium does not mean, however, that these cells are not
important in the pathogenesis, as a subset of specific T cells
may be sufficient to promote the inflammatory process, and
regulatory T cells may have anti-inflammatory effects. As a
matter of fact, T cells are likely to be involved in the
pathogenesis of psoriasis and PsA [26]. The infiltrate in
lesional psoriasis skin mainly consists of activated T cells. In
the synovial infiltrate, T cells are present among other cell
types, and oligoclonal T-cell expansions have been demon-
strated in both skin and synovium [27], suggesting that an
antigen-driven T-cell response could be promoting ongoing
inflammation. For T-cell migration to the skin, the chemo-
kine receptor CCR4 is necessary. Interestingly, the ligand for
CCR4, macrophage-derived chemokine (MDC, also known
as CCL22) was recently demonstrated within the synovial
membrane and in high concentrations in the synovial fluid of
RA and PsA patients [28]. The presence of MDC facilitates
migration of CCR4-expressing memory cells into the
inflamed joint, supporting the notion that MDC/CCR4 could
play a role in attracting skin-specific memory T cells to the
synovial compartment. The role of T cells is further under-
lined in psoriasis and PsA by the beneficial effect of
therapies against Tcells, such as cyclosporin A and alefacept
[29–31]. Interestingly, a recently published paper on the
effects of abatacept, a selective inhibitor of T-cell activation
via competitive binding to CD80 or CD86, in PsA
demonstrated the efficacy of using abatacept on joints, but
a less strong effect on skin [32]. Interleukin (IL)-17–
producing T-helper cells (Th17 cells) are a recently recog-
nized effector T-lymphocyte population playing a role in
chronic inflammatory conditions. IL-23 is highly expressed
in psoriatic plaques [33], and this cytokine is responsible for
stimulating Th17 cells that produce IL-17, as well as tumor
necrosis factor (TNF)-α,I L - 2 1 ,a n dI L - 2 2[ 34￿]. An
important role for Th17 cells has been demonstrated in
murine arthritis models [35]. The exact role of Th17 cells in
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cytokines IL-17 and IL-23 are expressed in the joints of PsA
and RA patients [36]. Clinical studies targeting the Th17 axis
are currently under way to establish the validity of this
therapeutic approach in patients with PsA. Moreover, block-
ing the p40 subunit, which is shared by IL-12 and IL-23,
leads to amelioration of arthritis in PsA [37].
Lymphoid aggregates of variable size and organization
level are not specific for RA but were observed in the
synovial biopsies of the majority of 27 PsA patients as well
[38]. Clear T-cell/B-cell segregation could be observed,
especially in the larger lymphoid aggregates, with many
features of lymphoid neogenesis present. Interestingly, a
complete response to treatment was associated with a
regression of the lymphoid aggregates.
Increased vascularity has been reported in both psoriatic
skinlesions andsynovialtissue.Inthedermisofpsoriatic skin,
an abundance of dilated and tortuous blood vessels is present
[39]. Several authors have reported that PsA synovium is
characterized by an increase in macroscopically tortuous
blood vessels, and this is more pronounced in—but not
exclusive to—PsA than it is in RA synovium [18–20, 40].
Consistent with the vascular abnormalities observed, over-
expression of vascular endothelial growth factor, which is
involved in angiogenesis, has been reported in immunohis-
tochemical analyses of both psoriatic skin [41] and PsA
synovial tissue, together with other vascular markers such as
von Willebrand’s factor, integrin αVβ3, and basic fibroblast
growth factor [15, 20, 21]. Upregulation of vascular adhesion
molecule 1, intercellular adhesion molecule 1 (ICAM-1), and
E-selectin has been reported in PsA synovium [15, 18]. These
adhesion molecules are involved in leukocyte adhesion and
penetration through the endothelium at sites of inflammation.
Interestingly, E-selectin appears to be upregulated in the skin
compared with the PsA synovial membrane, and cutaneous
lymphocyte–associated antigen is preferentially expressed on
leukocytes “homing” to psoriasis lesions, but not to the PsA
synovium [42].
A striking feature of PsA synovium is the abundant
overexpression of proinflammatory cytokines, including
TNF-α,I L - 1 β, IL-6, and IL-18 [15]. Another interesting
proinflammatory cytokine of the TNF ligand superfamily is
TNF-like weak inducer of apoptosis (TWEAK), a pleiotropic
cytokine that probably plays a physiologic role in tissue
repair via its receptor, Fn14, which is highly induced after
injury. The TWEAK/Fn14 pathway promotes local chemo-
kine and cytokine production, resulting in additional infiltra-
tion of proinflammatory cells, and facilitates angiogenesis and
the proliferation of progenitor cells needed for tissue repair.
TWEAK and Fn14 seem to be permanently activated in
chronic inflammation, however, and the mechanisms that are
beneficial for tissue repair can then contribute to persistent
inflammation. TWEAK blockade previously has been ob-
served to exert a beneficial effect in an animal model of
arthritis. The presence of TWEAK and Fn14 was recently
demonstrated in the inflamed synovium of patients with RA
and PsA [43]. This raises the possibility that blocking
TWEAK/Fn14 signaling could be of therapeutic benefit in
inflammatory arthritis.
Another new field of interest is the role of the nervous
system in inflammatory arthritis. Considerable evidence
indicates that the nervous system can modulate immune
responses in several immune-mediated diseases. The choliner-
gic anti-inflammatory pathway is characterized by neural
regulation of systemic inflammation, mediated by the vagus
nerve and specific cholinergic stimulation of the nicotinic α7
acetylcholine receptor (α7nAChR) on immune cells. Using
immunohistochemistry and double immunofluorescence mi-
croscopy, the expression of α7nAChR-positive cells in
synovial tissue from patients with RA and PsA was recently
demonstrated. The α7nAChR-positive cells were identified as
primarily macrophages and fibroblasts in the intimal lining
layer and in blood vessels [44￿]. This illustrates the potential
role of α7nAChR and cholinergic mechanisms controlling
arthritis. Another pivotal mediator of neurogenic inflammation
is nerve growth factor (NGF). NGF is found in serum,
synovial fluid, and cerebrospinal fluid and is highly expressed
in inflammatory and degenerative rheumatic diseases. NGF
concentrations correlate with the extent of inflammation and
clinical disease activity. NGF levels are significantly higher in
RA as compared with osteoarthritis [45￿]. These findings
support the possibility of therapeutic modulation of neuro-
genic inflammation by intervening with NGF or α7nAChR as
a potential anti-inflammatory therapeutic strategy in arthritis.
Taken together, although RA and PsA are clinically
separate diseases with different etiologies, the synovial
infiltrate in both conditions shows more similarities than
differences. On the group level, PsA synovium may have
less pronounced intimal lining layer hyperplasia and fewer
synovial T cells compared with RA, but the available
studies comparing synovial tissue are relatively small and
m a yb eb i a s e db ys e v e r a lc o n f o u n d i n gf a c t o r s .M o r e
importantly, there is overexpression of many proinflamma-
tory cytokines in the synovial tissue of active RA and PsA,
including TNF-α and IL-6. Future studies will show
whether interventions in newly discovered pathways, such
as the proinflammatory cytokine TWEAK, or neurogenic
inflammation could also be of therapeutic benefit to patients
with inflammatory arthritis.
Effects of Therapy on Psoriatic Arthritis Synovium
A few studies have been conducted in PsA to evaluate
synovial changes after therapy [46–51]. Open-label treatment
of 10 PsA patients with methotrexate resulted in a decrease in
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IL-8, E-selectin, ICAM-1, and matrix metalloproteinase 3
(MMP-3) after 6 to 12 months [46]. In another study, 52 SpA
patients with peripheral arthritis were included (16 of whom
were classified as PsA [47]) and underwent synovial biopsy
at baseline and 12 weeks following different treatment
regimens (infliximab, etanercept, sulfasalazine, or no
disease-modifying antirheumatic drug). Clinical improve-
ment in this study correlated with a decrease in CD163
+
macrophages, polymorphonuclear cells, and MMP-3 expres-
sion. Two other smaller studies demonstrated a significant
reduction in the expression of the adhesion molecule ICAM-
1 and the vascular markers von Willebrand’sf a c t o ra n dαVβ
in 11 and 9 PsA patients, respectively, treated with infliximab
[50, 51]. A study on the effects of alefacept revealed a
significant decrease in T-cell numbers after 4 weeks of
treatment and a significant reduction in both T cells and
macrophages after 12 weeks of treatment in 11 PsA patients
[48]. Finally, experimental treatment with IL-10 subcutane-
ously for 4 weeks in 28 patients resulted in decreased T-cell
and macrophage infiltration in the synovium [52].
From these studies, it can be concluded that successful
treatment in the long run always leads to deactivation of
endothelium, reduced vascularity, and a reduction in
infiltrating immune cells. Identical to the approach that we
have previously described in RA patients [53], we designed
a randomized, placebo-controlled study to determine which
early changes in synovial markers are associated with active
treatment on the group level [16￿]. For this purpose, 24
patients with active PsA were treated with adalimumab or
matched placebo at baseline and day 15. Synovial biopsies
were taken before and after 4 weeks of treatment. We
observed (trends toward) reduced numbers of macrophages
and macrophage subsets after active treatment, but a
statistically significant effect of treatment was only ob-
served for the reduction in CD3
+ T cells and the expression
of MMP-13 using analysis of covariance. In addition,
clinical improvement was strongly correlated with a
decrease in CD3
+ T cells, CD4
+ cells, and MRP8
+, as well
as MMP-13 and MMP-3. Thus, particularly the reduction of
T cells was correlated with effective therapy and clinical
improvement, which was confirmed by another recently
published study [54]. This underscores the importance of T
cells in the pathogenesis of PsA [26], consistent with the
observation that specific targeting of T cells may result in
clinical benefit in this disease [31, 48, 55].
Model for Proof-of-Concept Study Design
The rise in newly discovered drugs and potential
therapeutic targets currently under investigation will have
consequences for the way potential novel therapies are
tested in clinical trials. It will be increasingly difficult to
include large numbers of patients with active disease in
large, placebo-controlled trials because of the growing
number of compounds to be tested and the fact that
effective treatment is now available for many patients.
Therefore, in an early stage of drug development, it
could be useful to perform intensive trials with a small
number of patients in which large amounts of data are
collected to study the effects of the compound tested.
The identification of biomarkers that could be used for
prediction of the clinical response to treatment and
evaluation of biological effects of potential novel
therapies is of the utmost importance for this develop-
ment. Because synovial inflammation is one of the key
manifestations of PsA, we and others have focused on
the identification of synovial biomarkers [16￿, 54].
Sensitive synovial biomarkers could be used as predictors
of clinical effects in small proof-of-principle trials for
selection purposes, similar to the approach used in RA
[17]. Our study indicates that the reduction in the number
of CD3
+ cells and the expression of MMP-13 may be
candidate synovial biomarkers to screen for potentially
active drugs in small proof-of-concept studies of short
duration. As arthroscopic synovial biopsy is not available
in all centers, ultrasound-guided biopsy may be another
approach [56]. Alternatively, the identification of relevant
soluble biomarkers that can be measured in blood would
further facilitate the feasibility of small high-density-of-
data clinical trials that are conducted to screen for efficacy.
We propose that analysis of serial biopsies may be used as
a screening method to test new compounds requiring
relatively small numbers of participants. The absence of
changes in the synovial tissue after treatment on the group
level would suggest that the therapy is probably not
effective.
Conclusions
Most patients with PsA present with peripheral synovitis of the
oligoarticularorpolyarticularsubtype.Therefore,thesynovium
is, as a primary site of inflammation in this disease, an
important tissue to study. Several descriptive immunohisto-
chemical studies of the synovial tissue of patients with RA and
PsA show more similarities than differences between the two
inflammatory arthropathies, which could point to the activation
of common final pathways and similarities in synovial infiltrate
inestablisheddisease.On thegrouplevel,PsAsynoviummight
have less pronounced intimal lining layer hyperplasia, more
pronounced vascularity, and fewer synovial T cells compared
with RA, but the available studies comparing synovial tissue
are relatively small and may be biased by several confounding
factors. Effective treatment of patients with PsA in the long run
356 Curr Rheumatol Rep (2011) 13:353–359will lead to a resolution in synovial inflammation, including
deactivation of endothelium, fewer blood vessels, and a
reduction in infiltrating immune cells. Two recent studies
demonstrated that an early reduction in synovial T cells after
TNF blocking therapy correlated with clinical improvement.
Weproposeamodelforearlyproof-of-conceptstudiesinwhich
sensitive(synovial)biomarkersareusedaspredictorsofclinical
effect for selection purposes during early drug development. A
reduction in the number of CD3
+ cells and the expression of
MMP-13 are interesting candidate synovial biomarkers to
screen for potentially active drugs in small proof-of-principle
studies of short duration, alongside clinical outcome and
imaging measures.
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